TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03228719

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standardize PT after TKR with a Physical Activity Intervention
Description: Standardized PT and a physical activity intervention. Participants will be provided a FitbitTM Zip within one week after enrolling in the study. Participants will self-track their steps/day using their FitbitTM Zip. Participants ≤ 3 weeks' post-operative TKR are expected to maintain and not increase steps/day. Beyond 3 weeks after surgery, step goals will be initiated and evaluated on a weekly basis. Progression of weekly steps/day goal will be a joint decision between the participant and physical therapist. As a guide, a 10-20% increase in steps/day until at least 6,000 steps/day is achieved. Each week the physical therapist will review the participant's steps/day goal and if at least 4 of the 7 previous days per week were at or above the prior week's steps/day goal, then next week's steps/day goal will increase. The physical therapist will discuss current steps/day with the participant using the Fitbit TM Zip and set a personalized steps/day goal each week during PT.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standardized PT after TKR
Description: Participants in the control group will receive standardized PT provided by a licensed physical therapist at UDPT using the University of Delaware's Rehabilitation Guidelines for Unilateral Total Knee Replacement. Standardized PT also includes a printed home exercise program with an exercise log that is updated weekly by a physical therapist. PT appointment times range from 45-60 minutes with appointment occurring 1-3 times a week for 6-8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized PT after TKR
Description: Participants in the control group will receive standardized PT provided by a licensed physical therapist at UDPT using the University of Delaware's Rehabilitation Guidelines for Unilateral Total Knee Replacement. Standardized PT also includes a printed home exercise program with an exercise log that is updated weekly by a physical therapist. PT appointment times range from 45-60 minutes with appointment occurring 1-3 times a week for 6-8 weeks.
Study: NCT04350580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human immunoglobulin
Description: Human immunoglobulin 2g/kg over 4 days (0.5g/kg/d)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium chloride 0.9% in the same volume and over the same time as the immunoglobulin
Study: NCT02220166

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Triticum monococcum
Study: NCT03661047

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMR101 (VASCEPA, icosapent ethyl)
Description: Oral administration, 4 grams per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AMR101 (VASCEPA, icosapent ethyl)
Description: Oral administration, 4 grams per day
Study: NCT03409133

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimulating nerve electrodes and intramuscular recording electrodes
Description: See Arm Description
Study: NCT03753425

Intervention type: PROCEDURE
Intervention: Low volume bowel preparation in inflammatory bowel diseases
Description: Low volume bowel preparation in inflammatory bowel diseases
Study: NCT04329247

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Median nerve neural mobilization
Description: Manual therapy maneuver performed in the upper limb.
Study: NCT05479383

Intervention type: OTHER
Intervention: Not applicable, this is an observational study
Description: Not applicable, this is an observational study
Study: NCT04386278

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention 1
Description: Side one: No treatment Side two: OrthoPulse Gen 2 (2RP) for one minute

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention 2
Description: Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (2RP) for one minute

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention 3
Description: Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (2RP) for 5 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention 4
Description: Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (2RCW) for five minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention 5
Description: Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (3RB 2RL) for one minute

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention 6
Description: Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (3RB 2RL) for five minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention 7
Description: Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (3RB 2RL) for one minute
Study: NCT01550653

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04386278

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention 8
Description: Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (3RBP) for five minutes
Study: NCT02329678

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peripical surgery
Description: Thirty patients meeting inclusion criteria were selected and allocated randomly into two groups: collagen membrane group and control group. Clinical and radiographic measurements were recorded during follow up at regular intervals of 0, 3, 6, 9, and 12 months after surgery. The criteria for success included the absence of clinical signs and symptoms, and complete or incomplete radiographic healing.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peripical surgery
Description: Thirty patients meeting inclusion criteria were selected and allocated randomly into two groups: collagen membrane group and control group. Clinical and radiographic measurements were recorded during follow up at regular intervals of 0, 3, 6, 9, and 12 months after surgery. The criteria for success included the absence of clinical signs and symptoms, and complete or incomplete radiographic healing.
Study: NCT02400047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.2 mg/kg
Description: Single injection of DXM (Mylan Dexamethasone® 20 mg/5 ml or 4 mg/1 ml injection ampoule solution) at 0.2 mg / kg after general anesthesia induction and before surgery incision.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.4 mg/kg
Description: Single injection of DXM (Mylan Dexamethasone® 20 mg/5 ml or 4 mg/1 ml injection ampoule solution) at 0.4 mg / kg after general anesthesia induction and before surgery incision.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketoprofen 1 mg/kg
Description: Single injection of ketoprofen (Medac ketoprofen ® 100 mg/4 ml injection ampoule solution) at 1 mg /kg after general anesthesia induction and before surgery incision.
Study: NCT04125459

Intervention type: PROCEDURE
Intervention: Joint Biopsy
Description: a synovial biopsy of a joint that has been affected by a gout attack
Study: NCT02714647

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attentional prime

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham prime
Study: NCT02838355

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respiratory Depression Monitoring with End Tidal Carbon Dioxide Nasal Cannula (ETCO2- NC)
Description: The ETCO2-NC is a non-invasive device that monitors the amount of carbon dioxide that is exhaled with every breath.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Non-invasive Respiratory Depression Monitoring
Description: Standard non-invasive respiration monitoring includes telemetry of heart rate and rhythm, respiratory rate, blood pressure, CF-LVAD flow, and oxygen saturation (SpO2) via pulse oximetry.
Study: NCT00932750

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Coffee mannooligosaccharide
Description: 2 beverages daily providing either 4 g of coffee mannooligosaccharide or placebo.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Coffee mannooligosaccharides
Description: Subjects consume 2 beverages daily providing 4 g of coffee mannooligosaccharides or placebo
Study: NCT00481520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAM-531

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03286465

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pediatric phlebotomy tubes
Description: Use of pediatric size tubes for diagnostic blood collection.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Adult phlebotomy tubes
Description: Use of adult size tubes for diagnostic blood collection.
Study: NCT01297348

Intervention type: DRUG
Intervention: 90ug levonorgestrel / 20 ug ethinyl estradiol
Description: This is a non-interventional observational database study, thus no interventions are offered to patients in the study.

Intervention type: DRUG
Intervention: Oral Contraceptives containing 20 ug of ethinyl estradiol
Description: This is a non-interventional observational database study, thus no interventions are offered to patients in the study.
Study: NCT02757248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volasertib
Description: Volasertib 75-150mg/m2 given intravenously on days 1 and 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volasertib
Description: Volasertib 75-150mg/m2 given intravenously on days 1 and 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volasertib
Description: Volasertib 75-150mg/m2 given intravenously on days 1 and 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volasertib
Description: Volasertib 75-150mg/m2 given intravenously on days 1 and 8
Study: NCT02838355

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Non-invasive Respiratory Depression Monitoring
Description: Standard non-invasive respiration monitoring includes telemetry of heart rate and rhythm, respiratory rate, blood pressure, CF-LVAD flow, and oxygen saturation (SpO2) via pulse oximetry.
Study: NCT02757248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volasertib
Description: Volasertib 75-150mg/m2 given intravenously on days 1 and 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Romidepsin 12-14mg/m2 given intravenously on days 1, 8 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Romidepsin 12-14mg/m2 given intravenously on days 1, 8 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Romidepsin 12-14mg/m2 given intravenously on days 1, 8 and 15
Study: NCT02968537

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alc-IT (50/50) (morning)
Description: This alcohol-specific inhibition-training (Alc-IT) training group will operate with a Go/NoGo ratio of 50/50 (Houben et al. 2011; 2012): This original version of the Alc-inhibition-training will include 80 alcoholic NoGo trials as well as 80 non-alcoholic Go trials. In order to arrive at the same training length while keeping the number of Alc-NoGo-pairings constant and the Go/NoGo-ratio at 50/50, it will additionally include 80 neutral Go-trials as well as 80 neutral NoGo-trials. It will thus consist of 320 trials and take about 10.5 minutes to be completed. In the morning group, this training will be administered within the first 2 hours after awakening.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alc-IT (75/25) (morning)
Description: This version of the alcohol-specific inhibition-training (Alc-IT) will operate with a Go/NoGo-ratio of 75/25. It will equally include 80 Alcoholic NoGo-trials and 80 non-alcoholic Go-trials, but now 160 neutral Go-trials will complete the set. This training will also consist of 320 trials and take about 10.5 minutes. In the morning group, this training will be administered within the first 2 hours after awakening.
Study: NCT02757248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Romidepsin 12-14mg/m2 given intravenously on days 1, 8 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Romidepsin 12-14mg/m2 given intravenously on days 1, 8 and 15
Study: NCT05074537

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI exam
Description: Participants who are receiving standard of care or investigational MRI exams at the Wright Center will be eligible for enrollment in this data bank.

Intervention type: DIAGNOSTIC_TEST
Intervention: PET/CT imaging exam
Description: Participants who are receiving standard of care or investigational PET/CT exams at the Wright Center will be eligible for enrollment in this data bank.
Study: NCT03202277

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BeWell24 smartphone app
Description: This app delivers an evidence-based suite of lifestyle interventions targeting behavior change in sleep, sedentary behavior, physical activity, and dietary intake. The app connects with a commercially available activity monitor to provide real-time feedback on behaviors over time.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health education app
Description: This app delivers basic health education and hygiene content related to sleep, sedentary behavior, physical activity, and dietary intake.
Study: NCT01071122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine (Adalat, BAYA1040) and Valsartan
Description: Combination treatment with nifedipine GITS 30mg and valsartan 80mg, Once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine (Adalat, BAYA1040)
Description: Nifedipine 60mg, Once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: Valsartan 160mg, Once daily
Study: NCT01422538

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera® System
Description: Focused ultrasound energy delivered below the surface of the skin on the lower face.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sculptra®
Description: Injectable filler reconstituted prior to use. Injections are administered to the lower face in a combination of cross-hatching and fanning techniques. The Sculptra is injected in two treatment sessions 6 weeks apart.
Study: NCT02968537

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control-training (morning)
Description: This group will receive an unspecific inhibition training. this training is of the same length and difficulty as the two Alc-inhibition-trainings. In the morning group, this training will be administered within the first 2 hours after awakening.
Study: NCT01422538

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sculptra® treatment followed by Ultherapy™ treatment
Description: Sculptra® administered in 2 injection sessions 6 weeks apart, then Ultherapy™ treatment 4 months following Sculptra.
Study: NCT02968537

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alc-IT (50/50) (afternoon)
Description: As in the arm Alc-IT (50/50) (morning), this alcohol-specific inhibition-training (Alc-IT) group will operate with a Go/NoGo ratio of 50/50 (Houben et al. 2011; 2012): This original version of the Alc-inhibition-training will include 80 alcoholic NoGo trials as well as 80 non-alcoholic Go trials. In order to arrive at the same training length while keeping the number of Alc-NoGo-pairings constant and the Go/NoGo-ratio at 50/50, it will additionally include 80 neutral Go-trials as well as 80 neutral NoGo-trials. It will thus consist of 320 trials and take about 10.5 minutes to be completed. In contrast to the In the morning group, this afternoon group will receive the training in the afternoon.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alc-IT (75/25) (afternoon)
Description: As in the arm Alc-IT (75/25) (morning), this version of the alcohol-specific inhibition-training (Alc-IT) will operate with a Go/NoGo-ratio of 75/25. It will equally include 80 Alcoholic NoGo-trials and 80 non-alcoholic Go-trials, but now 160 neutral Go-trials will complete the set. This training will also consist of 320 trials and take about 10.5 minutes. In contrast to the In the morning group, this afternoon group will receive the training in the afternoon.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control-training (afternoon)
Description: As in the arm Control-training (morning), this group will receive an unspecific inhibition training. This training is of the same length and difficulty as the two Alc-inhibition-trainings. In contrast to the In the morning group, this afternoon group will receive the training in the afternoon.
Study: NCT03087799

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Treatment for Sleep
Description: The BBT arm will consist of 2 in-person treatment visits and 2 telephone check-in visits. Treatment will involve psychoeducation about sleep hygiene and stimulus control as well as sleep schedule modification and sleep restriction. The treatment manual is attached for clarification. This manual is used solely to guide clinical decision making and will not be provided to participants.
Study: NCT01760642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam 3 mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: ketoconazole 400 mg PO
Study: NCT00376623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 2536
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 2536
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 2536
Description: Intravenous Infusion
Study: NCT02937701

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABP 710
Description: Administered by intravenous infusion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: Administered by intravenous infusion
Study: NCT04504526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-Pentixafor
Description: Intravenous injection of one dose of 74-148 MBq (2-4 mCi) 68Ga-Pentixafor. Tracer doses of 68Ga- Pentixafor will be used to image lesions by PET/CT.
Study: NCT02218905

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sit to stand test
Description: Subjects will be asked to sit to stand in 40 inches chair for 60 seconds.
Study: NCT02281305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Study: NCT03109977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zr-DFO-pertuzumab PET/CT
Description: Zr-DFO-pertuzumab studies will be performed as hybrid PET/CT examinations with known HER2-positive malignancy
Study: NCT05123495

Intervention type: BEHAVIORAL
Intervention: Device Briefing Tool
Description: A 4-item supplement to the WHO Surgical Safety Checklist designed to improve teamwork and communication around new/complex surgical devices

Intervention type: BEHAVIORAL
Intervention: Surgical Safety Checklist
Description: Reimplementation of the WHO Surgical Safety Checklist to improve adherence and utility of the checklist

Intervention type: BEHAVIORAL
Intervention: Surgical Safety Checklist
Description: Reimplementation of the WHO Surgical Safety Checklist to improve adherence and utility of the checklist
Study: NCT04217265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole then misoprostol
Description: total dose 5 mg per day for 3 days then Misoprosrol 800mcg will be given to all patients for induction of abortion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo then misoprostol
Description: placebo tablets for 3 days then Misoprosrol 800mcg will be given to all patients for induction of abortion
Study: NCT02522767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalamine
Study: NCT01387737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-7284-Low
Description: TA-7284-Low

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-7284-High
Description: TA-7284-High
Study: NCT05074537

Intervention type: DIAGNOSTIC_TEST
Intervention: CT imaging exam
Description: Participants who are receiving standard of care or investigational CT exams at the Wright Center will be eligible for enrollment in this data bank.
Study: NCT04857177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-701
Description: CKD-701 (proposed ranibizumab biosimilar) 0.5mg via intravitreal injection every one month during the loading phase, and intervals of one month based on criteria during the PRN phase.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lucentis®
Description: Lucentis® (ranibizumab) 0.5mg via intravitreal injection every one month during the loading phase, and intervals of one month based on criteria during the PRN phase.
Study: NCT00705419

Intervention type: DRUG
Intervention: Vicriviroc maleate
Description: Follow-up for subjects who previously received 30 mg tablet administered once daily according to the parent protocol.

Intervention type: DRUG
Intervention: Vicriviroc maleate
Description: Follow-up for subjects who previously received 20 mg tablet administered once daily according to the parent protocol.

Intervention type: DRUG
Intervention: Placebo
Description: Follow-up for subjects who previously received placebo tablet administered once daily according to the parent protocol.

Intervention type: DRUG
Intervention: Emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg
Description: Follow-up for subjects who previously received active control consisting of emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg combination tablet administered once daily according to the parent protocol.
Study: NCT02802228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifetroban
Description: thromboxane prostanoid receptor antagonist delivered as infusion and oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matched placebo delivered as infusion and oral capsule
Study: NCT01983631

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole body vibration training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole body vibration training
Study: NCT02522767

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo